| 1 | 
                
                    TNFSF13B
                
             | 4件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | D03068 
                
                    D03068
                
             | 
                
                    Belimumab
                
             | 12件:  11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 | 
| 2 | 
                
                    CSF3R
                
             | 5件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235 
                
                    D03235
                
             | 
                
                    Filgrastim
                
             | 34件:  2 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 | 
| 3 | 
                
                    ADRA1D
                
             | 6件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 4 | 
                
                    ADRA1B
                
             | 6件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 5 | 
                
                    ADRA1A
                
             | 7件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 6 | 
                
                    ADRA2A
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 7 | 
                
                    ADRA2A
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008 
                
                    D01008
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 8 | 
                
                    ADRA2A
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461 
                
                    D07461
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 9 | 
                
                    ADRA2B
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 10 | 
                
                    ADRA2B
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008 
                
                    D01008
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 11 | 
                
                    ADRA2B
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461 
                
                    D07461
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 12 | 
                
                    ADRA2C
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 13 | 
                
                    ADRA2C
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008 
                
                    D01008
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 14 | 
                
                    ADRA2C
                
             | 2件:  cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461 
                
                    D07461
                
             | 
                
                    Apraclonidine
                
             | 1件:  11 11 | 
| 15 | 
                
                    ADRB1
                
             | 11件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 16 | 
                
                    ADRB2
                
             | 9件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 17 | 
                
                    ADRB2
                
             | 9件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147 
                
                    D02147
                
             | 
                
                    Salbutamol
                
             | 14件:  3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 | 
| 18 | 
                
                    ADRB3
                
             | 8件:  Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124 
                
                    D00124
                
             | 
                
                    Ephedrine
                
             | 1件:  11 11 | 
| 19 | 
                
                    DHFR
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142 
                
                    D00142
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 20 | 
                
                    DHFR
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115 
                
                    D02115
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 21 | 
                
                    DHODH
                
             | 3件:  Pyrimidine metabolism Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors | D00749 
                
                    D00749
                
             | 
                
                    Leflunomide
                
             | 12件:  11 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 | 
| 22 | 
                
                    DHFR2
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142 
                
                    D00142
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 23 | 
                
                    DHFR2
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115 
                
                    D02115
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 24 | 
                
                    FCGRT
                
             | - | D11666 
                
                    D11666
                
             | 
                
                    Nipocalimab
                
             | 5件:  11 11, 46, 49, 53, 61 | 
| 25 | 
                
                    FCGRT
                
             | - | D11876 
                
                    D11876
                
             | 
                
                    Efgartigimod alfa
                
             | 4件:  11 11, 14, 35, 63 | 
| 26 | 
                
                    FCGRT
                
             | - | D12182 
                
                    D12182
                
             | 
                
                    Rozanolixizumab
                
             | 3件:  11 11, 14, 63 | 
| 27 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407 
                
                    D00407
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 28 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472 
                
                    D00472
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 29 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473 
                
                    D00473
                
             | 
                
                    Prednisone
                
             | 46件:  11 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | 
| 30 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00751 
                
                    D00751
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 31 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00979 
                
                    D00979
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 32 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00980 
                
                    D00980
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 33 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00981 
                
                    D00981
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 34 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00982 
                
                    D00982
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 35 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01239 
                
                    D01239
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 36 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01998 
                
                    D01998
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 37 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02156 
                
                    D02156
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 38 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03301 
                
                    D03301
                
             | 
                
                    Prednisolone
                
             | 42件:  11 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 | 
| 39 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000 
                
                    D05000
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 40 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05001 
                
                    D05001
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 41 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05002 
                
                    D05002
                
             | 
                
                    Methylprednisolone
                
             | 46件:  11 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 42 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00300 
                
                    D00300
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 43 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00669 
                
                    D00669
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 44 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D02419 
                
                    D02419
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 45 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03285 
                
                    D03285
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 46 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03360 
                
                    D03360
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 47 | 
                
                    HRH1
                
             | 3件:  Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03854 
                
                    D03854
                
             | 
                
                    Diphenhydramine
                
             | 10件:  11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 | 
| 48 | 
                
                    IL6R
                
             | 12件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | D02596 
                
                    D02596
                
             | 
                
                    Tocilizumab
                
             | 21件:  2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 | 
| 49 | 
                
                    IL6R
                
             | 12件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | D11079 
                
                    D11079
                
             | 
                
                    Satralizumab
                
             | 2件:  11 11, 13 | 
| 50 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752 
                
                    D00752
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 51 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094 
                
                    D05094
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 52 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095 
                
                    D05095
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 53 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096 
                
                    D05096
                
             | 
                
                    Mycophenolic acid
                
             | 36件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | 
| 54 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752 
                
                    D00752
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 55 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094 
                
                    D05094
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 56 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095 
                
                    D05095
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 57 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096 
                
                    D05096
                
             | 
                
                    Mycophenolic acid
                
             | 36件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | 
| 58 | 
                
                    ITGAL
                
             | 12件:  Rap1 signaling pathway Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis | D03959 
                
                    D03959
                
             | 
                
                    Efalizumab
                
             | 9件:  11 11, 13, 37, 46, 49, 53, 61, 95, 96 | 
| 59 | 
                
                    JAK1
                
             | 27件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970 
                
                    D09970
                
             | 
                
                    Tofacitinib
                
             | 15件:  11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 | 
| 60 | 
                
                    JAK2
                
             | 24件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970 
                
                    D09970
                
             | 
                
                    Tofacitinib
                
             | 15件:  11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 | 
| 61 | 
                
                    JAK3
                
             | 15件:  Chemokine signaling pathway Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D09970 
                
                    D09970
                
             | 
                
                    Tofacitinib
                
             | 15件:  11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 | 
| 62 | 
                
                    KCNA4
                
             | 2件:  Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome | D10228 
                
                    D10228
                
             | 
                
                    Amifampridine
                
             | 3件:  3 3, 11, 12 | 
| 63 | 
                
                    KCNC3
                
             | 1件:  Spinocerebellar ataxia Spinocerebellar ataxia | D10228 
                
                    D10228
                
             | 
                
                    Amifampridine
                
             | 2件:  11 11, 12 | 
| 64 | 
                
                    KCND2
                
             | 1件:  Serotonergic synapse Serotonergic synapse | D10228 
                
                    D10228
                
             | 
                
                    Amifampridine
                
             | 2件:  11 11, 12 | 
| 65 | 
                
                    KCND3
                
             | 1件:  Spinocerebellar ataxia Spinocerebellar ataxia | D10228 
                
                    D10228
                
             | 
                
                    Amifampridine
                
             | 2件:  11 11, 12 | 
| 66 | 
                
                    ACHE
                
             | 2件:  Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00487 
                
                    D00487
                
             | 
                
                    Pyridostigmine
                
             | 4件:  3 3, 6, 11, 256 | 
| 67 | 
                
                    ACHE
                
             | 2件:  Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D08261 
                
                    D08261
                
             | 
                
                    Neostigmine
                
             | 1件:  11 11 | 
| 68 | 
                
                    PPP3CA
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107 
                
                    D00107
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 69 | 
                
                    PPP3CA
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 70 | 
                
                    PPP3CA
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556 
                
                    D08556
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 71 | 
                
                    PPP3CB
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107 
                
                    D00107
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 72 | 
                
                    PPP3CB
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 73 | 
                
                    PPP3CB
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556 
                
                    D08556
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 74 | 
                
                    PPP3CC
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107 
                
                    D00107
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 75 | 
                
                    PPP3CC
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 76 | 
                
                    PPP3CC
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556 
                
                    D08556
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 77 | 
                
                    PPP3R1
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107 
                
                    D00107
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 78 | 
                
                    PPP3R1
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 79 | 
                
                    PPP3R1
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556 
                
                    D08556
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 80 | 
                
                    PPP3R2
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107 
                
                    D00107
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 81 | 
                
                    PPP3R2
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 82 | 
                
                    PPP3R2
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556 
                
                    D08556
                
             | 
                
                    Tacrolimus
                
             | 34件:  2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 | 
| 83 | 
                
                    PSMB5
                
             | 8件:  Proteasome Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases | D03150 
                
                    D03150
                
             | 
                
                    Bortezomib
                
             | 16件:  11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 | 
| 84 | 
                
                    PTGS1
                
             | 5件:  Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217 
                
                    D00217
                
             | 
                
                    Acetaminophen
                
             | 18件:  3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 | 
| 85 | 
                
                    PTGS2
                
             | 22件:  Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217 
                
                    D00217
                
             | 
                
                    Acetaminophen
                
             | 18件:  3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 | 
| 86 | 
                
                    RRM1
                
             | 5件:  Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways | D01370 
                
                    D01370
                
             | 
                
                    Cladribine
                
             | 3件:  11 11, 13, 94 | 
| 87 | 
                
                    TOP2A
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D00125 
                
                    D00125
                
             | 
                
                    Etoposide
                
             | 11件:  11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 | 
| 88 | 
                
                    TOP2A
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D04107 
                
                    D04107
                
             | 
                
                    Etoposide
                
             | 11件:  11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 | 
| 89 | 
                
                    TOP2A
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D05522 
                
                    D05522
                
             | 
                
                    Pixantrone
                
             | 2件:  11 11, 13 | 
| 90 | 
                
                    TOP2B
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D00125 
                
                    D00125
                
             | 
                
                    Etoposide
                
             | 11件:  11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 | 
| 91 | 
                
                    TOP2B
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D04107 
                
                    D04107
                
             | 
                
                    Etoposide
                
             | 11件:  11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 | 
| 92 | 
                
                    TOP2B
                
             | 1件:  Platinum drug resistance Platinum drug resistance | D05522 
                
                    D05522
                
             | 
                
                    Pixantrone
                
             | 2件:  11 11, 13 | 
| 93 | 
                
                    C5
                
             | 10件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D03940 
                
                    D03940
                
             | 
                
                    Eculizumab
                
             | 7件:  11 11, 13, 14, 61, 62, 109, 222 | 
| 94 | 
                
                    C5
                
             | 10件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11054 
                
                    D11054
                
             | 
                
                    Ravulizumab
                
             | 7件:  2 2, 11, 13, 50, 62, 66, 109 | 
| 95 | 
                
                    C5
                
             | 10件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11477 
                
                    D11477
                
             | 
                
                    Pozelimab
                
             | 2件:  11 11, 62 | 
| 96 | 
                
                    TYK2
                
             | 16件:  Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 | D09970 
                
                    D09970
                
             | 
                
                    Tofacitinib
                
             | 15件:  11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 | 
| 97 | 
                
                    CD19
                
             | 5件:  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, B cell receptor signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | D11757 
                
                    D11757
                
             | 
                
                    Inebilizumab
                
             | 4件:  11 11, 13, 51, 300 | 
| 98 | 
                
                    MS4A1
                
             | 1件:  Hematopoietic cell lineage Hematopoietic cell lineage | D02994 
                
                    D02994
                
             | 
                
                    Rituximab
                
             | 48件:  11 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 | 
| 99 | 
                
                    CD80
                
             | 10件:  Cell adhesion molecules Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203 
                
                    D03203
                
             | 
                
                    Abatacept
                
             | 26件:  11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 | 
| 100 | 
                
                    CD86
                
             | 12件:  Cell adhesion molecules Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203 
                
                    D03203
                
             | 
                
                    Abatacept
                
             | 26件:  11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |